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Abstract Fatty acid utilization is initiated by fatty acid-CoA
ligase, which converts free fatty acids into fatty acyl-CoA esters.
We have cloned previously the human long-chain fatty acid-CoA
ligase 4 (FACL4), which is a central enzyme in controlling the
free arachidonic acid level in cells and thereby regulating
eicosanoid production. We report here the expression of this
gene in tissues, particularly in different parts of the brain. We
found that FACL4 encoded a 75 kDa enzyme and that there was
a modified translation product expressed in the brain. FACL4
was expressed in early stages of development with a significant
amount of FACL4 mRNA detected in an E7 mouse embryo. In
addition, FACL4 was highly expressed in both adult and newborn
mouse brain especially in the granule cells of the dentate gyrus
and the pyramidal cell layer of CA1 in hippocampus, and the
granular cell layer and Purkinje cells of the cerebellum.
z 2000 Federation of European Biochemical Societies.
Key words: Arachidonic acid; Fatty acid-CoA ligase;
Gene expression; Mouse embryo; Hippocampus
1. Introduction
Arachidonic acid (AA; 20:4, n-6), an essential polyunsatu-
rated fatty acid, is a substrate for an important class of lipid
mediators, eicosanoids, including prostaglandins, thrombox-
anes and leukotrienes [1]. Free AA in cells is normally main-
tained at a low level, so constitutive eicosanoid synthesis is
limited under unstimulated conditions. AA entering cells exo-
genously or released endogenously is rapidly converted to
AA-CoA esters by the catalytic action of fatty acid-CoA li-
gase (FACL), particularly by the AA-preferring FACL4 [2,3].
FACL is a key enzyme in controlling the free fatty acid pools
and is essential for usage of free fatty acids as building blocks
and energy sources. To date, ¢ve isoforms of this gene have
been cloned in mammals with diverse substrate speci¢city and
tissue distribution [3,4]. We have reported previously the clon-
ing and tissue expression pattern of the isoform 4 of FACL in
humans [3]. Compared to other isoforms, isoform 4 of both
human and rat highly prefers AA and eicosapentanoic acid
(EPA) as substrates [3,5]. Therefore, FACL4 plays an impor-
tant role in AA metabolism. Our previous analysis by North-
ern blotting indicated that FACL4 is highly expressed in
brain, placenta, testis, ovary, spleen and adrenal cortex. In-
terestingly, we noticed that a di¡erent size of FACL4 mRNA
was present in brain compared to that in other tissues, which
suggested a brain-speci¢c alternative transcript [3]. To eluci-
date more on tissue-speci¢c and developmental regulation of
FACL4 expression, we further characterized the protein ex-
pression of FACL4 in the brain and other tissues, the mRNA
and protein expression pattern in brain structure of mice, and
mRNA expression during development.
FACL4 was found to be deleted in a family with Alport
syndrome, elliptocytosis, and mental retardation [6]. This
raised the possibility that de¢ciency of FACL4 contributes
to the development of mental retardation. Therefore, determi-
nation of expression pattern of FACL4 in brain structure and
during development will be fundamental in understanding the
potential role of FACL4 in brain function.
2. Materials and methods
2.1. Immunoblotting
The experiment was performed as described previously [7]. A poly-
clonal anti-FACL4 antibody was raised in rabbit against a synthesized
peptide ‘H2N-MAKRIKAKPTSDKPGC-amide’ which corresponds
to the deduced N-terminal sequence of human FACL4. The anti-
FACL4 antibody was then a⁄nity-puri¢ed and used as the primary
antibody (1:3000 dilution). In peptide competition, the FACL4 N-
terminal peptide (0.1 mg/ml) was incubated with the anti-FACL4 anti-
body at a 10:1 (v/v) ratio overnight at 4‡C before the antibody was
applied to the blot. This anti-FACL4 antibody subsequently was
found to cross-react with mouse FACL4 in both Western blotting
and immunostaining.
2.2. Northern blotting
This analysis was carried out as described previously [3]. Digoxige-
nin-labeled RNA probes were prepared by in vitro transcription using
the DIG RNA-labeling kit (Boehringer Mannheim). The mouse
FACL4 cDNA construct pSL147 was linearized by EcoRI or EcoRV
digestion, and an anti-sense RNA probe of 682 bp was generated
under the catalytic action of T3 RNA polymerase. The complemen-
tary sense probe was produced by T7 RNA polymerase, and used as a
control for in situ hybridization.
2.3. Immunohistochemical staining
Para⁄n-embedded mouse embryo sections were purchased from
Novagen. The sections were depara⁄nized and the endogenous per-
oxidase was eliminated by incubating in 3% hydrogen peroxide for
5 min. Adult and newborn mouse brains were embedded in OCT
medium (VWR) and 6 WM thick sections were picked up on Super-
frost Plus slides (Fisher Scienti¢c). The sections then were ¢xed in
cold acetone for 10 min. The endogenous peroxidase in the tissues
was eliminated by incubating in 0.1% hydrogen peroxide for 15 min.
The sections were blocked by incubating with 5% normal goat serum,
1% bovine serum albumin for 30 min, and then the anti-FACL4 anti-
body was diluted 1:200, applied to the slides and incubated overnight.
A secondary antibody (biotin-conjugated goat anti-rabbit, Jackson
Immunoresearch) was applied at a 1:1000 dilution and incubated
for 30 min. Positive control was performed using an S-100 antibody
(Sigma), and negative controls consisted of omitting the anti-FACL4
antibody, and/or secondary antibody, or pre-incubating the antibody
with the immunizing peptide overnight. ABC reagent was prepared
according to the manufacturer’s instructions (Vector Laboratories)
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and applied to the sections for 30 min. The signal was detected using a
3,3-diaminobenzidine tetrahydrochloride (DAB) kit (Vector Labora-
tories), followed by counterstaining with Gill’s hematoxylin, dehydrat-
ing, and mounting with Cytoseal 60 medium (VWR).
2.4. Tissue in situ hybridization
Both anti-sense and sense (negative control) RNA probes were
prepared as described above, and diluted to 1 Wg/ml in hybridization
bu¡er (50% formamide, 2USSC, 10% dextran sulfate, 0.01% herring
sperm DNA, 0.02% SDS). After dehydration of the slides, 20 Wl of the
probe solution was applied to each slide. The slides were heated to
95‡C for 4 min followed by hybridization at 55‡C for 4 h.
Post-hybridization washes consisted of 2USSC overnight, three
times in 50% formamide/1USSC for 20 min at 55‡C, twice in
1USSC for 15 min, and a ¢nal rinse in 1UTBS. The sections were
blocked in 5% normal sheep serum, 0.03% Triton X-100 in Bu¡er
1 (100 mM Tris^HCl, pH 7.5, 150 mM NaCl) for 15 min, and then
200 Wl of detection antibody (alkaline phosphatase-conjugated mouse
anti-biotin, Jackson Immunoresearch) was applied for 1 h. The slides
were washed three times in Bu¡er 1 for 10 min, and then equilibrated
in Bu¡er 3 (100 mM Tris^HCl, pH 9.5, 100 mM NaCl, 50 mM
MgCl2) for 5 min. They subsequently were immersed in substrate
solution (4.5 Wl/ml NBT, 3.5 Wl/ml BCIP in Bu¡er 3) and allowed
to develop for 60 min. The reaction was terminated in Bu¡er 4
(10 mM Tris^HCl, pH 8.0, 1 mM EDTA), and the slides were coun-
terstained with Nuclear Fast Red, and mounted with Cytoseal 60
(VWR).
3. Results
3.1. FACL4 protein has a di¡erent electrophoretic mobility in
the brain and is not detectable in the liver
Our previous results by Northern analysis revealed that
FACL4 mRNA has a di¡erent size in the brain compared
to other tissues, and that little mRNA was detected in the
liver. To determine the protein expression in di¡erent tissues,
we examined the expression of FACL4 protein in the human
heart, brain and liver by Western blotting (Fig. 1). One spe-
ci¢c band corresponding to 75 kDa was detected in the heart,
and mobility of the band was the same as in the control,
which was HEK293 epithelial cells transiently transfected
with a human FACL4 cDNA. There also was a band of ap-
parently higher molecular weight in control cells and the brain
lysates which also could be competed away with the FACL4
peptide. Whether this is a precursor of FACL4 or another
isoform of FACL that cross-reacts with the FACL4 antibody
is not clear. In contrast to the heart, with the same amount of
whole protein lysate, no FACL4 protein was detected in the
liver, which agrees with the previous ¢nding that there is an
extremely low mRNA level in the liver [3]. These two ¢ndings
suggest that a low rate of transcription of the FACL4 gene is
the basis for the low level of protein in the liver. In addition,
we observed a FACL4 band with a slightly faster mobility in
the brain (Fig. 1). Densitometry analysis indicated that the
FACL4 band was 5.5-fold more intensive in the brain than
that in the heart, indicating that FACL4 protein is expressed
at a much higher level in the brain than in the heart.
3.2. FACL4 is expressed during early development
Previously, we have observed that human FACL4 is ex-
Fig. 1. Expression of FACL4 protein in human tissues. One hun-
dred Wg of whole protein lysate from various tissues (Clontech), and
50 Wg of lysate from 293 cells transiently transfected with a human
FACL4 cDNA construct (control) were separated by SDS^PAGE.
The blot was probed with the anti-FACL4 antibody which was pre-
incubated with or without the N-terminal peptide of FACL4. The
binding was speci¢c as it was blocked by pre-incubation with the
FACL4 N-terminal peptide. 3 Peptide, without peptide competi-
tion; + Peptide, with peptide competition. Arrowhead 1 points to
the position of FACL4 bands in the cell lysate and the heart, and
arrowhead 2 indicates that in the brain.
Fig. 2. Expression of FACL4 during early development. (a) North-
ern blot analysis of the expression of FACL4 during mouse embry-
onic development. One Wg of poly(A) RNA from mouse embryos
of 7, 11, 15 and 17 days old, respectively was separated and then
immobilized to the membrane (Clontech). Northern blot analysis
was carried out by hybridizing to a digoxigenin-labeled probe con-
taining the anti-sense mouse FACL4 RNA. The blot was also
probed with a L-actin anti-sense RNA for loading normalization.
The number to the left hand side indicates the position of the size
marker. (b) Immunohistochemical staining of the E10 and E13
mouse embryonic sections (40U). 3 Peptide, without peptide com-
petition (panels 1 and 3); + Peptide, with peptide competition (pan-
els 2 and 4). The arrowhead in panel 1 indicates the positive signals
in the neural tube. The arrowhead in panel 3 refers to the staining
in the hindbrain. Scale bar = 80 Wm.
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pressed widely in various adult tissues [3]. We next asked if
FACL4 is expressed during early stages of development using
Northern blot analysis. A mouse anti-sense RNA probe was
prepared, and hybridized to poly(A) RNAs from mouse em-
bryos of 7, 11, 15 and 17 days old, respectively. A single band
of 5.0 kb was detected in all samples (Fig. 2a). The expres-
sion levels of FACL4 in prenatal mice were similar except
that in the E7 embryo which appeared even higher than in
the older embryos. We noticed that the intensity of the inter-
nal control band, L-actin, was also high in the E7 embryo
mRNA, so it is likely that the intensive band of FACL4
resulted from overloading. Next, we performed immunohisto-
chemical staining with sections from E10 and E13 mouse em-
bryos, and the results con¢rmed that FACL4 was expressed in
embryos (Fig. 2b). Moreover, strong staining was detected in
the central and peripheral nervous systems. Speci¢cally, the
lining of the neural tube was positively stained in the E10
embryo (Fig. 2b, panel 1), as was the hindbrain, and regions
of the spinal cord in the E13 embryo (Fig. 2b, panel 3). We
conclude that the FACL4 gene is expressed early during de-
velopment, and that expression is detectable as early as the E7
embryo.
3.3. FACL4 is highly expressed in the hippocampus and
cerebellum
In our pilot in situ hybridization with the whole mouse
brain, the hippocampus and cerebellum appeared to have a
strong expression of FACL4 mRNA (data not shown). To
examine the distribution of FACL4 in the structure of devel-
oping and adult brains, we performed immunohistochemical
staining and in situ hybridization on mouse brain sections. We
found that hippocampal sections from either newborn or
adult brain (Fig. 3a, b, d, e) stained positively with the anti-
FACL4 antibody. The speci¢c staining patterns (Fig. 3a, b, d,
e versus peptide competition controls c, f) indicated that
FACL4 is highly expressed in the hippocampus in both new-
born and adult brains: we detected strong signals in the
densely packed granule cells of the dentate gyrus (Fig. 3e)
and also the pyramidal cell layer of region CA1 (Fig. 3b).
In addition, the staining pattern in the cerebellum of newborn
and adult mice was examined. Compared to the adult cerebel-
lum (panel i), the structure of the newborn cerebellum is not
fully established yet, and showed morphology with less char-
acteristics (panels g, h). The dense granular layer of both
newborn and adult showed a strong signal (Fig. 3g, i). The
Fig. 3. Expression of FACL4 in mouse hippocampus and cerebellum. a through k are immunohistochemical staining with the anti-FACL4 anti-
body. a, b, c are hippocampal coronal sections of newborn mice (6 24 h postpartum), and d, e, f are sagittal sections from the hippocampus
of adult mice. b and e show the indicated cropped regions in a and d under higher magni¢cation. g and h are coronal sections of newborn cer-
ebellum, and i and k are sagittal sections of adult cerebellum. j is the enlarged view of the cropped region in i, and the arrowheads indicate
the positively stained Purkinje cells. In c, f, h and k, the antibody was pre-incubated with the FACL4 peptide (negative controls). l, m, n are
in situ hybridization with the FACL4 anti-sense (l, m) and sense (n, control) RNA probes. m is an enlarged view of the cropped region in
l under higher magni¢cation. DG, dentate gyrus; Py, pyramidal cell layer; G, granule cells; CA1, region CA1. a through k were counterstained
with hematoxylin. l through n were counterstained with Nuclear Fast Red. Magni¢cation: a, d, l are 10U, and all the rest are 40U. Scale
bar = 320 Wm for panels a, d, l. Scale bar = 80 Wm for panels b, c, e, f, g, h, i, k, m, n.
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Purkinje cell, which is the only output element of the cerebel-
lar cortex and forms the sole link between the cerebellar cor-
tex and the cerebellar nuclei, also stained positively (Fig. 3j).
In parallel, serial sections of the section shown in Fig. 3d were
hybridized to FACL4 RNA probes (Fig. 3l, m, n). A high
level of expression of FACL4 was detected in the granule cells
using the anti-sense RNA probe (panel m), which is consistent
with the immunostaining pattern (panel e). In situ hybridiza-
tion to the adult cerebellum also showed a similar expression
pattern as revealed by the immunohistochemical staining
(data not shown). Taken together, these results indicate that
FACL4 is highly expressed in the hippocampus and cerebel-
lum.
4. Discussion
The absence of the FACL4 gene in a family of non-syn-
dromic X-linked mental retardation raised the possibility that
de¢ciency of this gene could lead to Xq23-linked mental re-
tardation. So far, ¢ve unrelated pedigrees with mental retar-
dation have been characterized around Xq22V26 (MRX 23,
27, 30, 35, 47) [8^12], and only one of them (MRX 30) has
been identi¢ed as a mutation in PAK3 (p21-activated kinase)
[13]. Our immunohistochemical staining and in situ hybrid-
ization results showed that the expression pattern of FACL4
is very similar to PAK3 in developing and adult brain, sug-
gesting that FACL4 could play an important role in normal
brain functions, particularly in learning and memory. There-
fore, de¢ciency of this gene might have serious clinical con-
sequences.
Neuropsychological studies and neurophysiological experi-
ments have revealed that the hippocampus plays a key role in
certain aspects of learning and memory, and the cerebellum is
essential to the execution of speci¢c movements, i.e. motor
coordination. The strong expression of FACL4 in both the
hippocampus and the cerebellum suggests that the function of
this enzyme may be essential to the normal function of these
two structures. We speculate that this is the consequence of
the structural and regulatory roles of the product of FACL4,
arachidonoyl-CoA esters. In addition, this enzyme may also
exert e¡ects on normal brain function via controlling the free
AA pool, as it has been shown that AA uptake and metabo-
lism are dynamically regulated in brain, and AA acts directly
on several aspects of brain function [14,15].
In a previous study, expression of other isoforms of FACL
was detected at di¡erent levels in adult rat brains of varying
ages [16]. Here we detected expression of the AA-preferring
FACL4 in prenatal mice. Whether other isoforms are also
expressed in the embryonic stages awaits investigation. The
expression of FACL1 mRNA was at a constant level during
postnatal brain development. In contrast, FACL2 mRNA in-
creased gradually and reached a maximum in the adult brain,
and FACL3, which is highly expressed in the brain, showed
an increase in the early stages and a dramatic decrease in the
late stages of postnatal development of rat adult brain [16].
We observed a higher expression of FACL4 mRNA in new-
born than in adult mouse brain by in situ hybridization, which
also suggests that this isoform may be developmentally regu-
lated. The presence of multiple FACL isoforms in the brain
and the di¡erential regulation during development suggest
that each isoform plays a distinct role in brain lipid metabo-
lism. It is likely that each isoform is regulated spatially and
temporally. Also, each isoform may localize to a subset of
intracellular membranes, may prefer a speci¢c fatty acid
pool, then may drive the free fatty acids to di¡erent metabolic
pathways. This hypothesis is supported by the observation
that triacsin C exerted di¡erential e¡ects on lipid synthesis :
it blocked synthesis of neutral lipids but not the incorporation
of fatty acids into phospholipids [17]. One interpretation is
that di¡erent FACL isoforms divert fatty acid into separate
pathways of lipid synthesis, and these isoforms vary in their
sensitivity to triacsin C.
Our previous Northern analysis suggests the presence of an
alternative transcript in the brain. This transcript is most
likely to result from transcription driven by a brain-speci¢c
promoter, and alternative splicing occurs between the ¢rst and
second exons. In this study, we observed a FACL4 protein
band with a di¡erent electrophoretic mobility in the brain
which raised the possibility of tissue-speci¢c alternative trans-
lation. The presence of heterogeneous amino termini has been
reported in the FACL3 isoform, which is also highly ex-
pressed in the brain [18]. However since the anti-FACL4 anti-
body was raised against the most N-terminal sequence of
FACL4 (see Section 2) and it could bind to both the brain
and the heart forms of FACL4 (Fig. 1), it is unlikely that
these two forms result from alternative translation. More
likely, the di¡erent mobility is due to proteolysis, or post-
translational modi¢cations such as N-glycosylation. It has
been shown previously that some membrane proteins are pro-
duced from precursors by furin-like proteinase. Amino acid
sequence [3] analysis revealed that there is a basic tetrapeptide
near the C-terminus of FACL4, from position 649 to 652
(KLKR) which is similar to a consensus sequence for proteo-
lytic cleavage by furin-like proteinase [RX(K/R)R] [19]. In
addition, there are two putative sites for N-glycosylation, lo-
cated at amino acid residues 153 and 484 which match the
consensus sequence, NXS/T [20]. Whether these potential sites
are responsible for post-translational modi¢cation in a tissue-
speci¢c manner awaits further investigation.
There was no detectable mRNA expression of FACL4 in
human liver [3] in contrast to the high expression in the hippo-
campus and cerebellum, especially during early stages of de-
velopment. This suggests that FACL4 might not be essential
for the synthesis of fuel components, which is a major func-
tion of the liver, whereas it might be central in AA recycling
into phospholipids, particularly in the brain. The presence of
an alternative transcript and a di¡erent FACL4 protein prod-
uct in the brain strongly suggests that the expression and
subcellular distribution of FACL4 could be regulated di¡er-
entially in the brain compared to other tissues, and this type
of regulation has been reported in previous examples [21,22].
The distribution of FACL4 in brain structure suggests that
the function of the FACL4-derived arachidonoyl phospholip-
ids may relate to intellectual capability and coordination
skills.
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